FibroBiologics, Inc. Common Stock
FBLGHealthcare|Biotechnology|US
$0.98
+0.02 (+2.39%)
DCF Value
$0.73
Tangible Book / Share
$1.23
Cash / Share
$0.93
Financials
Financial Snapshot
Market Cap
$6.5M
Enterprise Value
$4.5M
Revenue (TTM)
$0.00
Net Income (TTM)
-$18.1M
Cash & Investments
$3.5M
Net Cash
$2.1M
Free Cash Flow (TTM)
-$14.8M
Operating CF (TTM)
-$14.8M
Debt/Equity
0.32
Cash Runway & Burn Rate
Cash on Hand
$3.5M
Quarterly Burn
$3.7M
Monthly Burn
$1.2M
Est. Runway
~1.0 quarters
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $0.00 | $407.0K | $2.3M | $9.2M | $14.0M | $4.9M | $3.5M | |
| Operating Cash Flow | -$1.2M | -$1.4M | -$4.1M | -$6.4M | -$11.9M | -$16.4M | -$14.8M | |
| Free Cash Flow | -$1.2M | -$1.4M | -$4.1M | -$6.9M | -$12.1M | -$16.7M | -$14.8M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | -$495.0K | -$184.0K | -$262.0K | -$6.0K | |
| Financing Cash Flow | $1.2M | $1.8M | $5.9M | $13.8M | $16.9M | $7.6M | $9.5M |
R&D Spending
R&D (TTM)
$8.2M
R&D Intensity
—
R&D Growth vs Prior
+10.7%
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $669.0K | $521.0K | $1.1M | $2.4M | $4.5M | $7.4M | $8.2M | |
| SG&A | $500.0K | $1.1M | $3.3M | $6.5M | $9.2M | $9.2M | $8.5M |
Income Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $832.0K | $234.0K | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$832.0K | -$234.0K | |
| R&D | $669.0K | $521.0K | $1.1M | $2.4M | $4.5M | $7.4M | $8.2M | |
| SG&A | $500.0K | $1.1M | $3.3M | $6.5M | $9.2M | $9.2M | $8.5M | |
| Operating Income | -$1.2M | -$1.6M | -$4.5M | -$8.9M | -$13.7M | -$16.6M | -$16.7M | |
| Interest Expense | $0.00 | $4.0K | $654.0K | $147.0K | $20.0K | $204.0K | $215.0K | |
| Pretax Income | -$1.2M | -$1.6M | -$5.1M | -$16.5M | -$11.2M | -$18.6M | -$18.1M | |
| Net Income | -$1.2M | -$1.6M | -$5.1M | -$16.5M | -$11.2M | -$18.6M | -$18.1M | |
| EPS (Diluted) | -0.72 | -0.97 | -3.20 | -11.80 | -6.80 | -8.35 | -6.00 | |
| EBITDA | $0.00 | -$1.6M | -$4.4M | -$15.9M | -$10.6M | -$17.6M | -$17.0M | |
| Shares Out. (M) | 1.62 | 1.62 | 1.62 | 1.62 | 1.64 | 2.23 | 3.77 |
Balance Sheet
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $0.00 | $407.0K | $2.3M | $9.2M | $14.0M | $4.9M | $3.5M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $0.00 | $468.0K | $2.6M | $9.2M | $14.2M | $6.3M | $5.8M | |
| Total Assets | $0.00 | $468.0K | $4.8M | $11.8M | $16.4M | $9.6M | $7.9M | |
| Total Current Liabilities | $0.00 | $1.8M | $7.1M | $9.2M | $12.7M | $1.8M | $2.2M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.1M | |
| Total Liabilities | $0.00 | $1.8M | $8.8M | $10.6M | $13.7M | $3.5M | $3.3M | |
| Stockholders' Equity | $0.00 | -$1.3M | -$4.0M | $1.3M | $2.7M | $6.2M | $4.6M | |
| Retained Earnings | -$1.2M | -$2.8M | -$7.9M | -$24.4M | -$35.5M | -$54.2M | -$63.3M |
Cash Flow Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.2M | -$1.4M | -$4.1M | -$6.4M | -$11.9M | -$16.4M | -$14.8M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | -$495.0K | -$184.0K | -$262.0K | -$6.0K | |
| Free Cash Flow | -$1.2M | -$1.4M | -$4.1M | -$6.9M | -$12.1M | -$16.7M | -$14.8M | |
| Investing Cash Flow | $0.00 | $0.00 | $0.00 | -$495.0K | -$184.0K | -$262.0K | -$6.0K | |
| Financing Cash Flow | $1.2M | $1.8M | $5.9M | $13.8M | $16.9M | $7.6M | $9.5M | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $7.5M | $6.6M | $12.7M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $1.5M | $3.8M | $300.0K | $9.4M | $975.0K | -$3.3M | |
| Stock Based Comp. | $0.00 | $0.00 | $265.0K | $1.8M | $2.2M | $2.7M | $2.8M | |
| Net Change in Cash | $0.00 | $407.0K | $1.9M | $6.9M | $4.8M | -$9.1M | -$5.3M |
Dilution Tracker
Shares outstanding grew 37.5% over 5 years — significant dilution
Shares Outstanding
7M
5-Year Share Growth
+37.5%
Stock Issuance (TTM)
$12.7M
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 1.62 | 1.62 | 1.62 | 1.62 | 1.64 | 2.23 | 3.77 | |
| Change vs Prior % | — | -0.0% | 0.0% | 0.0% | 1.2% | 35.8% | 69.0% | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $7.5M | $6.6M | $12.7M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $265.0K | $1.8M | $2.2M | $2.7M | $2.8M |
Margins & Profitability
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| ROE % | 0.0% | 122.6% | 128.2% | -1315.6% | -408.1% | -302.9% | -536.8% | |
| ROA % | 0.0% | -338.0% | -106.2% | -139.5% | -67.9% | -193.8% | -228.8% | |
| ROIC % | 0.0% | -15780.0% | -126.6% | -296.3% | -103.4% | -194.4% | -274.3% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | -35.0% | -183.1% | -99.0% | -54.5% | -21.2% | |
| Net Income | 0.0% | -35.3% | -223.7% | -221.9% | 32.3% | -67.1% | |
| EPS (Diluted) | 0.0% | -35.3% | -228.5% | -268.8% | 42.4% | -22.8% | |
| Operating Cash Flow | 0.0% | -20.6% | -188.4% | -57.4% | -85.9% | -37.8% | |
| Free Cash Flow | 0.0% | -20.6% | -188.4% | -69.6% | -75.2% | -37.8% | |
| R&D Expense | 0.0% | -22.1% | 120.2% | 106.5% | 90.2% | 64.5% | |
| SG&A Expense | 0.0% | 111.4% | 214.1% | 96.4% | 41.6% | 0.1% | |
| Total Assets | 0.0% | 0.0% | 930.8% | 145.0% | 39.1% | -41.5% | |
| Book Value / Share | 0.0% | 0.0% | -209.8% | 131.3% | 115.7% | 65.7% | |
| Debt | 0.0% | 0.0% | 478.8% | -76.8% | 504.1% | -77.2% | |
| Diluted Shares | 0.0% | -0.0% | 0.0% | 0.0% | 1.2% | 35.8% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.80
10Y Low / Med / High1.63 / 24.04 / 754.60
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.73
Tangible Book / Share
$1.23
Net Current Assets / Share
$0.38
Graham Net-Net
$0.06
Cash / Share
$0.93
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -808.33 | -597.54 | -181.88 | -49.32 | -5.88 | -0.54 | -0.16 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 0.00 | -732.63 | -236.51 | 754.60 | 24.04 | 1.63 | 0.80 | |
| EV/EBITDA | 0.00 | -599.48 | -217.32 | -59.00 | -5.90 | -0.43 | -0.26 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-16.86
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $7.5M |
| Net Income | -$6.7M | -$7.3M | -$10.7M |
| EPS | $-3.00 | $-3.25 | $-4.00 |
| # Analysts (EPS) | 1 | 1 | 3 |